Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02021838 · ClinicalTrials.gov registry record
Evaluation of the Office on Violence Against Women's Domestic Violence Homicide Prevention Demonstrative Initiative
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 666
- Enrollment target
NCT02021838: Completed study, sponsored by Yale University.
NCT02021838 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 666 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02021838 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 666 participants
- Enrollment target
Study Summary
In collaboration with the National Institute of Justice (NIJ) and the Office for Violence Against Women (OVW) the Yale University team will evaluate the implementation process and impact of the U.S. Department of Justice's Domestic Violence Homicide Prevention Demonstration Initiative. This evaluation seeks to draw critical findings and potential lessons from the combined experience of the sites including: 1) how the models work in different communities; 2) the barriers and facilitators to implementing the models; and 3) outcomes of the model delivery. The evaluation team will also disseminate the findings with the goal of informing replication.
Primary Outcome
Decrease in harassment, assault, injury, homicide/mortality
Interventions
- OTHER Lethality Assessment Program
- OTHER Domestic Violence High Risk Team
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 666 participants |
| Start Date | 2014-01-01 |
| Est. Completion | 2020-12-31 |
What the finished NCT02021838 record still lists
NCT02021838 is an observational study that tracks outcomes without assigning an intervention. The registered 666 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Lethality Assessment Program is the first listed.
NCT02021838 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02021838 about?
NCT02021838 is a clinical study titled "Evaluation of the Office on Violence Against Women's Domestic Violence Homicide Prevention Demonstrative Initiative". In collaboration with the National Institute of Justice (NIJ) and the Office for Violence Against Women (OVW) the Yale University team will evaluate the implementation process and impact of the U.S. Department of Justice's Domestic Violence Homicide Prevention Demonstration Initiative. This evaluati...
What is the current status of trial NCT02021838?
This trial is currently completed. The enrollment target is 666 participants. The study started on 2014-01-01. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT02021838?
The interventions under investigation include: Lethality Assessment Program (OTHER), Domestic Violence High Risk Team (OTHER).
Who is sponsoring clinical trial NCT02021838?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
- NCT06981078 · 666 participants · Phase 2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT04155034 · 668 participants · Phase 3
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI